PharmaPoint: Heart Failure – Global Drug Forecast and Market Analysis to 2025
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
GlobalData estimates sales of HF therapeutics to be approximately $3.2B across the 7MM in 2015, encompassing the US, 5EU, and Japan. The HF market will grow at a strong CAGR of 13.5% over the forecast period, reaching sales of $11.5B by 2025. The 7MM chronic HF market size in 2015 was $3.1B, and is expected to increase to $10.1B by 2025 at a CAGR of 12.7%. The US was the largest market for chronic HF therapies, contributing 61.2% of total sales in the base year. GlobalData expects uptake of Novartis' Entresto to be the strongest driver of the chronic HF and total HF markets in the 7MM, reaching peak sales of $5.9B in 2022. The acute HF market is expected to increase from just $188.1M in 2015 to $1.5B in 2025, at a CAGR of 23.0%. Japan dominated the acute HF market in the base year, 2015, accounting for 86.0% of market share. However, with the launch of several acute HF add-on therapies in the forecast period, the US will take over as the acute HF market leader, contributing 68.7% of sales to the acute HF market by 2025.
Scope
Overview of HF, both chronic and acute, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
Annualized HF therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the chronic and acute HF therapeutics markets.
Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
Analysis of the current and future market competition in the global HF therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Key Highlights
The level of unmet needs in the HF market is significantly high. Will the pipeline drugs fulfil these unmet needs of the market? Key Opinion Leaders (KOLs) interviewed by GlobalData provide insights and highlight opportunities for drug developers.
The HF market is crowded with cheap, generic, “me-too” drugs, making it a particularly difficult market to penetrate. The current late-stage pipeline consists of several chronic HF therapies, and three novel acute HF therapies. How will the market be impacted by the launch of these drugs? Which of the marketed and pipeline drugs will have the highest peak sales at the highest CAGR, and why?
Will Entresto become the new standard-of-care in the chronic HF market? What are the main barriers a new therapy faces when entering the HF market?
Bayer
BMS
Cardiorentis
Cytokinetics
Daiichi Sankyo Co. Ltd.
Heart Metabolics Ltd.
Lee’s Pharmaceutical Holdings Ltd.
Les Laboratoires Servier
Merck & Co.
Novartis
Ono Pharmaceuticals
Pfizer
Trevena Inc.
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.